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Stimulating an endogenous regenerative response is a powerful approach for potential treatment of chronic
demyelinating diseases such as multiple sclerosis. Recently in Nature, Najm et al. (2015) identified two
clinically relevant, FDA-approved compounds that promote oligodendrocyte progenitor cell differentiation
and induce remyelination in demyelinating disease models.Received wisdom is that the adult
mammalian central nervous system
(CNS) is not a good regenerator. While un-
doubtedly true for neurons, which are not
widely generated de novo after damage
nor readily regenerate damaged axons,
the same cannot be said for glia and, in
particular, oligodendrocytes. Oligoden-
drocytes are the myelinating cells of the
CNS that protect and promote neuronal
function, and loss of these cells, for
instance in diseases such as multiple
sclerosis (MS), results in demyelination
of axons, compromising their activity
and survival. Axons require an intact
myelin sheath to sustain their integrity,
and persistent demyelination leaves
them vulnerable to irreversible and cumu-
lative degeneration. The regeneration of
lost oligodendrocytes is in many ways
a paradigmatic example of regenera-
tion: replacement oligodendrocytes are
generated after injury-induced activation,
recruitment and differentiation of a wide-
spread population of multipotent adult
neural stem cells, commonly referred
to as oligodendrocyte progenitor cells
(OPCs). These newly generated oligoden-
drocytes restore the original architecture
and function of the damaged tissue
(Franklin and ffrench-Constant, 2008).
This is termed remyelination, and it is a
true regenerative process. So, if remyeli-
nation works, why then is there an urgent
need for remyelination-enhancing thera-
pies and why is a recent study by Najm
and colleagues (Najm et al., 2015), which
reports the identification of two small mol-
ecules with such activity, such a signifi-
cant advance toward meeting this need?
The efficiency of remyelination declines
progressively with aging (van Wijngaar-576 Cell Stem Cell 16, June 4, 2015 ª2015 Eden and Franklin, 2013). In chronic demy-
elinating diseases such as MS, the effi-
ciency of remyelination declines to the
point where, to all intents and purposes,
it fails. Thus, promotion of remyelination,
in addition to restoring lost function,
should also result in axon preservation.
The principal bottleneck in remyelination
that occurs with aging is the failure of re-
cruited oligodendrocyte lineage cells to
differentiate into new oligodendrocytes,
and undifferentiated oligodendrocyte
lineage cells are frequently observed in
areas of chronic demyelination in MS pa-
tients. Previous work using the hetero-
chronic parabiosis model has demon-
strated that the effects of aging are
reversible, and that when provided with
the correct environmental signals, old
adult OPCs can remyelinate as efficiently
as young adult OPCs (Ruckh et al.,
2012). This implies that overcoming the
declining efficiency of remyelination with
aging can be achieved in principle by
pharmacological means rather than by
cell therapy, spurring the quest in many
laboratories to identity targets that drive
OPC differentiation.
Tesar and colleagues (Najm et al.,
2015), using a similar approach to several
other recent studies (Deshmukh et al.,
2013; Mei et al., 2014), performed pheno-
typic screens using small molecule li-
braries to reveal compounds that promote
oligodendrocyte differentiation. Najm
et al. screened a library of bioactive small
compounds with a history of safe use in
clinical trials, thereby providing immediate
translational value, to identify molecules
that induce differentiation of mouse
epiblast-derived OPCs. This approach
identified two FDA-approved drugs, mi-lsevier Inc.conazole and clobestasol, the first a
topical antifungal agent and the second a
potent topical corticosteroid, that are
both able to cross the blood-brain barrier.
While the initial screen was based on the
ability of tested compounds to enhance
production of membrane sheet-forming
oligodendrocytes in vitro, the two drugs
were then tested inwhatmaywell become
a standard hierarchical series of experi-
mental models of myelination/remyelina-
tion of increasing complexity. Both com-
pounds showed activity in ex vivo slice
preparations of developmental myelina-
tion, toxin-induced demyelination in adult
rodent spinal cord, and experimental
autoimmune encephalomyelitis (EAE),
an immune-mediated model of CNS
inflammation believed to most closely
model the pathology of MS. Finally,
to verify the translational value of data
generated from rodents, both drugs were
found to induce differentiation of human
OPCs derived from hESCs and hiPSCs.
Analysis of the OPC signaling path-
ways likely influenced by these drugs re-
vealed that clobetasol activity is medi-
ated through the glucocorticoid receptor
signaling axis, while miconazole functions
through MEK-dependent activation of
Erk1/2.
The use of EAE models for assessing
remyelination is not without substantial
difficulties. Though proven valuable for
understanding the immunopathogenesis
of MS, there is the possibility that the ther-
apeutic manipulation being tested may
have direct effects on the adaptive im-
mune response on which the EAE model
is based. If the intervention were to
suppress this response then the degree
of demyelination may be reduced,
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myelination. Additionally, if the treatment
removes a response inimical to the oligo-
dendrocyte lineage, remyelination could
occur at its natural tempo but not neces-
sarily be enhanced (akin to allowing a
car to go faster by removing the hand-
brake rather than pressing the acceler-
ator). Najm and colleagues, attentive to
these possibilities, go to some pains to
show that their treatments do not influ-
ence the adaptive immune response,
and therefore that the beneficial effects
of miconazole and clobestasol on EAE
are likely due to direct enhancement of re-
myelination. However, only a few of the
many versions of the EAE model involve
bona fide primary demyelination in which
there are intact yet demyelinated axons
available for remyelination, which further
adds to the possibility of confused inter-
pretation of observations. In light of these
reservations, there should always be
critical evaluation of the necessity of the
EAE model, which was developed to un-
derstand CNS autoimmunity, as part of
the remyelination validation pipeline to
confirm regenerative neurobiology.
In the last few years, remyelination
biology has moved rapidly to the brink
of clinical application. The recognitionthat approved drugs, including an RXR
agonist and muscarinic receptor antago-
nists (Huang et al., 2011; Deshmukh
et al., 2013; Mei et al., 2014) in addition to
the two identified by Najm and colleagues,
can enhance remyelination in pre-clinical
models makes the prospects of clinical tri-
als a long-sought reality. Indeed, encour-
aging results of the first of these, a phase
2 trial using antibodies to Lingo-1, have
recently been reported at this year’s
meeting of the American Academy
of Neurology Annual meeting (https://
www.aan.com/conferences/2015-annual-
meeting/).Whileadeeperunderstandingof
the biology underlying remyelination and
the identification of more potential targets
will continue tobe important areas of future
research, perhaps the most important and
urgent challenges that we are now faced
with relate to clinical translation.Which pa-
tients will benefit most from remyelination
therapies, and at what stage of disease
should these be administered? What are
the most reliable outcome measure of
such therapies? How should remyelination
therapies be optimally coordinated with
immunosupression? These are just some
examples of the many questions that
need urgent answers. It is a testament to
the progress and excitement in the MSCell Stem Ceregenerative medicine field and the signifi-
cant strides that studies such as that by
Najm and colleagues have made that we
are now in a position to be even asking
such clinically relevant questions.REFERENCES
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